HARROW, INC. (HROWM)
2025-06-30 | ||||
|---|---|---|---|---|
| Total revenues | 63,742 | |||
| Cost of sales | 16,230 | |||
| Gross profit | 47,512 | |||
| Selling, general and administrative | 33,235 | |||
| Research and development | 2,868 | |||
| Total operating expenses | 36,103 | |||
| Income (loss) from operations | 11,409 | |||
| Other (expense) income, net | -6 | |||
| Interest expense, net | 6,408 | |||
| Investment loss from eton pharmaceuticals | - | |||
| Total other expense, net | -6,414 | |||
| Income (loss) before income taxes | 4,995 | |||
| Income tax expense | - | |||
| Net income (loss) | 4,995 | |||
| Basic net income (loss) per share of common stock | 0.14 | |||
| Diluted net income (loss) per share of common stock | 0.13 | |||
| Weighted average number of shares of common stock outstanding, basic | 36,790,306 | |||
| Weighted average number of shares of common stock outstanding, diluted | 38,853,855 | |||